Cargando…

1364. Efficacy of Omadacycline Against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials

BACKGROUND: Omadacycline (OMC) is a once-daily agent with IV and oral formulations. One Phase 3 trial for community-acquired bacterial pneumonia (CABP; OPTIC) and two Phase 3 trials for acute bacterial skin and skin structure infections (ABSSSI; OASIS-1 and OASIS-2) were completed. OMC and comparato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendes, Rodrigo E, Castanheira, Mariana, Armstrong, Eliana S, Steenbergen, Judith N, Flamm, Robert K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252834/ http://dx.doi.org/10.1093/ofid/ofy210.1195

Ejemplares similares

1377. Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
por: Mendes, Rodrigo E, et al.
Publicado: (2018)

1620. Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens
por: Shorttidge, Dee, et al.
Publicado: (2020)

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022)

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates
por: Mendes, Rodrigo E., et al.
Publicado: (2016)

1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections
por: Sader, Helio S, et al.
Publicado: (2019)

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens
por: Shortridge, Dee, et al.
Publicado: (2021)

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2020)

1523. Antimicrobial Activity of Ceftazidime–Avibactam and Comparator Agents Tested Against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program
por: Sader, Helio S, et al.
Publicado: (2018)

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions
por: Pfaller, Michael A., et al.
Publicado: (2017)

In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
por: Huband, Michael D, et al.
Publicado: (2017)

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
por: Sader, Helio S, et al.
Publicado: (2017)

690. Activity of a Novel Polymyxin Analog, QPX9003, Tested Against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas
por: Castanheira, Mariana, et al.
Publicado: (2019)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

Microbiology and Preclinical Review of Omadacycline
por: Karlowsky, James A, et al.
Publicado: (2019)

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2022)

2427. Comparison of Ceftazidime–Avibactam and Ceftolozane-Tazobactam In Vitro Activities When Tested Against Gram-Negative Bacteria Isolated From Patients Hospitalized With Pneumonia in US Medical Centers (2017)
por: Sader, Helio S, et al.
Publicado: (2018)

Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens
por: Lee, Ching-Yu, et al.
Publicado: (2011)

Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin
por: She, Pengfei, et al.
Publicado: (2022)

Novel Antimicrobial Agents for Gram-Negative Pathogens
por: Karvouniaris, Marios, et al.
Publicado: (2023)

1000. Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated From Patients Hospitalized With Bacteremia in United States and European Medical Centers: Results From the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2018)

Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
por: Kakoullis, Loukas, et al.
Publicado: (2021)

1308. Activity of Cefiderocol and Comparators against Gram-negative Isolates from US Patients Hospitalized with Pneumonia
por: Shortridge, Dee, et al.
Publicado: (2021)

Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
por: Livermore, David M.
Publicado: (2012)

Heme Uptake and Utilization by Gram-Negative Bacterial Pathogens
por: Richard, Kaylie L., et al.
Publicado: (2019)

Thymine Sensitizes Gram-Negative Pathogens to Antibiotic Killing
por: Liu, Yuan, et al.
Publicado: (2021)

Secretion Systems in Gram-Negative Bacterial Fish Pathogens
por: Mekasha, Sophanit, et al.
Publicado: (2021)

Bioengineered Nisin A Derivatives with Enhanced Activity against Both Gram Positive and Gram Negative Pathogens
por: Field, Des, et al.
Publicado: (2012)

Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability
por: Citron, Diane M., et al.
Publicado: (2011)

Determining the Risk of Antimicrobial Resistance in Common Gram-Positive and Gram-Negative Pathogens After Antibiotic Exposure
por: Hudson, Nicholas, et al.
Publicado: (2015)

Fumaric Acid and Slightly Acidic Electrolyzed Water Inactivate Gram Positive and Gram Negative Foodborne Pathogens
por: Tango, Charles Nkufi, et al.
Publicado: (2015)

Effect of Natural Zeolite (Clinoptilolite) on in vitro Biogenic Amine Production by Gram Positive and Gram Negative Pathogens
por: Özogul, Fatih, et al.
Publicado: (2018)

Cerium Oxide Nanoparticles and Their Efficient Antibacterial Application In Vitro against Gram-Positive and Gram-Negative Pathogens
por: Pop, Oana L., et al.
Publicado: (2020)

2192. Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia when Tested against Tazobactam Combinations
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

Think (Gram) negative!
por: Huttner, Benedikt, et al.
Publicado: (2010)

1261. Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019
por: Sader, Helio S, et al.
Publicado: (2020)

1598. Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime–Zidebactam (WCK-5222) Tested Against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections
por: Castanheira, Mariana, et al.
Publicado: (2019)

Charge effect on the photoinactivation of Gram-negative and Gram-positive bacteria by cationic meso-substituted porphyrins
por: Alves, Eliana, et al.
Publicado: (2009)

In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis
por: Steenbergen, Judith, et al.
Publicado: (2017)

Modulation of Quorum Sensing and Biofilms in Less Investigated Gram-Negative ESKAPE Pathogens
por: Lazar, Veronica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qt1ab9pmg7v2n4fupi077tq32r